Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T9TJ
|
|||
| Former ID |
DAP000053
|
|||
| Drug Name |
Orlistat
|
|||
| Synonyms |
orlistat; 96829-58-2; Tetrahydrolipstatin; Xenical; Alli; Orlipastat; (-)-Tetrahydrolipstatin; Orlipastatum; Orlipastatum [INN-Latin]; THLP; Ro-18-0647; UNII-95M8R751W8; C29H53NO5; Ro 18-0647/002; N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester; (2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoate; Orlistat (Alli, Xenical); MLS002207022; [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate; CHEMBL175247; Alli; GlaxoSmithKline brand of orlistat; Roche brand of orlistat; Alli (TN); Hoffmann-La Roche brand of orlistat; KS-1183; Orlistat [USAN:INN]; R-212; Xenical (TN); Orlistat (USAN/INN); Ro 18-0647/008; Alli, Xenical, Tetrahydrolipstatin, Orlistat; N-Formyl-L-leucine, ester with (3S,4S)-3-hexyl-4-((2S)-2-hydroxytridecyl)-2-oxetanone; L-Leucine, N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester; L-Leucine,N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester; 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate; TETRAHYDROLIPSTATIN
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Approved | [1], [2], [3], [4] | |
| Therapeutic Class |
Antiobesity Agents
|
|||
| Company |
GlaxoSmithKline plc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H53NO5
|
|||
| Canonical SMILES |
CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O
|
|||
| InChI |
1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1
|
|||
| InChIKey |
AHLBNYSZXLDEJQ-FWEHEUNISA-N
|
|||
| CAS Number |
CAS 96829-58-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7980207, 10047880, 11528795, 12013644, 14810727, 14933128, 17398010, 24724564, 26719846, 29217614, 36077810, 46386654, 46508309, 49681644, 51044514, 56269518, 56365491, 57352838, 92308398, 92717140, 93167011, 93576635, 93815140, 103436517, 104253266, 111635568, 117682959, 118048581, 124658856, 124757388, 124893192, 125164192, 125268639, 125311705, 126592933, 126622459, 126670765, 127407306, 134337381, 134346495, 134358631, 135027708, 135727048, 136023849, 136946428, 137001362, 143126586, 143495309, 144116319, 152034294
|
|||
| ChEBI ID |
CHEBI:94686
|
|||
| ADReCS Drug ID | BADD_D01624 | |||
| SuperDrug ATC ID |
A08AB01
|
|||
| SuperDrug CAS ID |
cas=096829582
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Inhibitor | [5] |
| Pancreatic triacylglycerol lipase (PNLIP) | Target Info | Modulator | [6] | |
| BioCyc | Triacylglycerol degradation | |||
| Retinol biosynthesis | ||||
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Glycerolipid metabolism | ||||
| Metabolic pathways | ||||
| Pancreatic secretion | ||||
| Fat digestion and absorption | ||||
| Vitamin digestion and absorption | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| Retinoid metabolism and transport | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| Visual phototransduction | ||||
| Lipid digestion, mobilization, and transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003007) | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5277). | |||
| REF 4 | Obesity and pharmacologic therapy. Endocrinol Metab Clin North Am. 2003 Dec;32(4):1005-24. | |||
| REF 5 | Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9. | |||
| REF 6 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.